Table 2 Flow of selection and patient characteristics of 324,708 individuals with a diagnosis of T2D in 2015

Number of patients in age and gender stratified database 2015

3, 876,632

and age ≥ 18 at 01.01.2015

3,296,948 / 100%

and observable between 2010 and 2015

3,229,909 / 98.0%

and diagnosis of T2D in 2015 - > Study population

324,708 / 9.9%

Female gender: Of study population / of all female insurants

48.6% / 9.3%

Male gender: Of study population / proprtion of all male insurants

51.4% / 10.4%

Age (years): Mean study population / mean female / mean male

70.0 / 71.8 / 68.2

Proportion of study population < 40

1.5%

Proportion of study population > =40 < 60

18.0%

Proportion of study population > =60 < 80

58.1%

Proportion of study population > =80

22.4%

 5 years and more

72.3%

 4 years

7.5%

 3 years

5.9%

 2 years

5.7%

 1 year

5.1%

 Incident diabetes diagnosis 2015

3.6%

 Hypertension

84.9%

 Lipometabolic disorder

59.4%

 At least one macrovascular event^a

14.3%

 At least one microvascular event^a

1.7%

 T2D related hospitalization^a

3.4%

 Glucose-lowering pharmacotherapy

69.9%

 Total non-insulin monotherapy

28.0%

 Metformin monotherapy

23.0%

 Sulfonylurea monotherapy

2.2%

 DPP4 inhibitor monotherapy

2.1%

 GLP-1 receptor agonist monotherapy

0.1%

 SGLT-2 inhibitor monotherapy

0.1%

 Glinide monotherapy

0.4%

 Glucosidase inhibitor monotherapy

0.1%

 Combination of two non-insulin glucose-lowering drugs

11.7%

 Combination of Metformin and Sulfonylurea

3.3%

 Combination of Metformin and DPP4

6.6%

 Combination of three or more non-insulin glucose-lowering drugs

3.5%

 Insulin therapy

26.6%

 Insulin only

12.3%

 Insulin plus at least one non-insulin glucose-lowering drug

14.3%